Press releases
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
Intravacc announces a $633K grant from CARB-X to develop a preventive Neisseria gonorrhoeae (NG) vaccine. Gonorrhea, the second most reported bacterial STI, affected 82 million globally in 2020, with limited antibiotic options. CARB-X supports Intravacc's innovative meningococcal outer membrane vesicle (OMV) vaccine, targeting gonococcal antigens for enhanced efficacy. Dr. Erin Duffy, CARB-X R&D Chief, highlights the project's potential to prevent the disease and combat global antibiotic resistance. Dr. Jan Groen, CEO of Intravacc, underscores the project's significance in addressing the antimicrobial resistance epidemic.
